

Digestive Health

New Clinical Breakthrough: IBS Human Clinical Trial Results

Presented by Nigel Plummer PhD

Teleconference Recorded Apr. 1, 2009

A newly published-blind, randomized, placebo-controlled study has shown that the LAB4 proprietary strains present in HMF Intensive probiotics reduces the symptoms of Irritable Bowel Syndrome (IBS).¹ This trial, including two strains of *Lactobacillus acidophilus* CUL60 (NCIMB 30157 and CUL21 (NCIMB 30156), *Bifidobacterium lactis* CUL34 (NCIMB 30172) and *Bifidobacterium bifidum* CUL 20 (NCIMB 301534) resulted in significantly greater improvement in symptom severity, bowel habit and quality of life.

¹ EA Williams, L Stimpson, D Wang, S Plummer, I Garaiova, ME Barker & BM Corfe. *Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study.* 2008; (9): 10.1111/j.1365-2036.2008.03848.x

